Surgical treatment of complex enterocutaneous fistulas in IBD patients using human acellular dermal matrix

Inflammatory Bowel Diseases

Volumn 15, Issue 8, 2009, Pages 1208-1212

  Taner, Timucin ^a   Cima, Robert R ^a   Larson, David W ^a   Dozois, Eric J ^a   Pemberton, John H ^a   Wolff, Bruce G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acellular dermal matrix; Enterocutaneous fistula; Infammatory bowel disease

Indexed keywords

MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ABDOMINAL WALL CLOSURE; ACELLULAR DERMAL MATRIX; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CROHN DISEASE; CRYOPROTECTION; ENTEROCUTANEOUS FISTULA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; SEROMA; SURGICAL APPROACH; SURGICAL TECHNIQUE; ULCERATIVE COLITIS; WOUND INFECTION;

ABDOMINAL WALL; ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL FISTULA; MALE; MIDDLE AGED; RECONSTRUCTIVE SURGICAL PROCEDURES; SKIN, ARTIFICIAL; SURGICAL MESH;

EID: 70349492480     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20882     Document Type: Article

References (14)

1. Edmunds LH Jr, Williams GM, Welch CE. External fistulas arising from the gastro-intestinal tract. Ann Surg. 1960;152:445-471.
2. Evenson AR, Fischer JE. Current management of enterocutaneous fistula. J Gastrointest Surg. 2006;10:455-464.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
4. Lynch AC, Delaney CP, Senagore AJ, et al. Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery. Ann Surg. 2004;240:825-831.
5. Poritz LS, Gagliano GA, McLeod RS, et al. Surgical management of entero and colocutaneous fistulae in Crohn's disease: 17 year's experience. Int J Colorectal Dis. 2004;19:481-485.
6. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;2:CD000545.
7. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998;93:442-448.
8. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125:380-388.
9. Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn's disease. Aliment Pharmacol Ther. 2006;24:1283-1293.
10. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
11. Hommes DW, van de Heisteeg BH, van der Spek M, et al. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis. 2002;8:81-86.
12. van Bodegraven AA, Sloots CE, Felt-Bersma RJ, et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39-45.
13. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
14. Jamshidi R, Schecter WP. Biological dressings for the management of enteric fistulas in the open abdomen: a preliminary report. Arch Surg. 2007;142:793-796.